Development of a Mimotope Vaccine Targeting the Staphylococcus aureus Quorum Sensing Pathway

A major hurdle in vaccine development is the difficulty in identifying relevant target epitopes and then presenting them to the immune system in a context that mimics their native conformation. We have engineered novel virus-like-particle (VLP) technology that is able to display complex libraries of random peptide sequences on a surface-exposed loop in the coat protein without disruption of protein folding or VLP assembly. This technology allows us to use the same VLP particle for both affinity selection and immunization, integrating the power of epitope discovery and epitope mimicry of traditional phage display with the high immunogenicity of VLPs. Previously, we showed that using affinity selection with our VLP platform identifies linear epitopes of monoclonal antibodies and subsequent immunization generates the proper antibody response. To test if our technology could identify immunologic mimotopes, we used affinity selection on a monoclonal antibody (AP4-24H11) that recognizes the Staphylococcus aureus autoinducing peptide 4 (AIP4). AIP4 is a secreted eight amino acid, cyclized peptide produced from the S. aureus accessory gene regulator (agrIV) quorum-sensing operon. The agr system coordinates density dependent changes in gene expression, leading to the upregulation of a host of virulence factors, and passive transfer of AP4-24H11 protects against S. aureus agrIV-dependent pathogenicity. In this report, we identified a set of peptides displayed on VLPs that bound with high specificity to AP4-24H11. Importantly, similar to passive transfer with AP4-24H11, immunization with a subset of these VLPs protected against pathogenicity in a mouse model of S. aureus dermonecrosis. These data are proof of principle that by performing affinity selection on neutralizing antibodies, our VLP technology can identify peptide mimics of non-linear epitopes and that these mimotope based VLP vaccines provide protection against pathogens in relevant animal models.

[1]  B. Chackerian,et al.  Virus-like particles: flexible platforms for vaccine development , 2007, Expert review of vaccines.

[2]  J. Schiller,et al.  Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. , 2010, Vaccine.

[3]  F. DeLeo,et al.  Mouse model of Staphylococcus aureus skin infection. , 2013, Methods in molecular biology.

[4]  Adeline R. Whitney,et al.  Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. , 2010, The Journal of infectious diseases.

[5]  I. Wilson,et al.  Structural Basis for Ligand Recognition and Discrimination of a Quorum-quenching Antibody* , 2011, The Journal of Biological Chemistry.

[6]  C. Malone,et al.  Fluorescent reporters for Staphylococcus aureus. , 2009, Journal of microbiological methods.

[7]  K. Janda,et al.  Generation of quorum quenching antibodies. , 2011, Methods in molecular biology.

[8]  G. Cheng,et al.  Neutrophil-derived IL-1β Is Sufficient for Abscess Formation in Immunity against Staphylococcus aureus in Mice , 2012, PLoS pathogens.

[9]  D. Sturdevant,et al.  Role of the Accessory Gene Regulator agr in Community-Associated Methicillin-Resistant Staphylococcus aureus Pathogenesis , 2011, Infection and Immunity.

[10]  P. Pumpens,et al.  Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). , 2006, Vaccine.

[11]  A. Tissot,et al.  Versatile Virus-Like Particle Carrier for Epitope Based Vaccines , 2010, PloS one.

[12]  R. Novick,et al.  Transient interference with staphylococcal quorum sensing blocks abscess formation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Bhakdi,et al.  Release of interleukin-1 beta associated with potent cytocidal action of staphylococcal alpha-toxin on human monocytes , 1989, Infection and immunity.

[14]  D. Peabody,et al.  Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. , 2008, Journal of molecular biology.

[15]  Junguk Park,et al.  Infection control by antibody disruption of bacterial quorum sensing signaling. , 2007, Chemistry & biology.

[16]  Martin F. Bachmann,et al.  The coming of age of virus-like particle vaccines , 2008, Biological chemistry.

[17]  H. Gresham,et al.  Apolipoprotein B Is an innate barrier against invasive Staphylococcus aureus infection. , 2008, Cell host & microbe.

[18]  D. Peabody,et al.  Stability and assembly in vitro of bacteriophage PP7 virus-like particles , 2007, Journal of nanobiotechnology.

[19]  D. Peabody,et al.  Thermal Stability of RNA Phage Virus-Like Particles Displaying Foreign Peptides , 2011, Journal of nanobiotechnology.

[20]  J. B. Wardenburg,et al.  Genetic Requirement for ADAM10 in Severe Staphylococcus aureus Skin Infection , 2011, The Journal of investigative dermatology.

[21]  R. Daum,et al.  Importance of the Global Regulators Agr and SaeRS in the Pathogenesis of CA-MRSA USA300 Infection , 2010, PloS one.

[22]  A. Kennedy,et al.  Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA , 2007, Nature Medicine.

[23]  Adeline R. Whitney,et al.  Comparative analysis of USA300 virulence determinants in a rabbit model of skin and soft tissue infection. , 2011, The Journal of infectious diseases.

[24]  Brook E. Ragle,et al.  Anti-Alpha-Hemolysin Monoclonal Antibodies Mediate Protection against Staphylococcus aureus Pneumonia , 2009, Infection and Immunity.

[25]  O. Schneewind,et al.  Vaccine protection against Staphylococcus aureus pneumonia , 2008, The Journal of experimental medicine.

[26]  R. Woods,et al.  Identification of Anti-Alpha Toxin Monoclonal Antibodies That Reduce the Severity of Staphylococcus aureus Dermonecrosis and Exhibit a Correlation between Affinity and Potency , 2012, Clinical and Vaccine Immunology.

[27]  C. Davis,et al.  Alpha and beta chains of hemoglobin inhibit production of Staphylococcus aureus exotoxins. , 2007, Biochemistry.

[28]  D. Peabody,et al.  Peptide epitope identification by affinity selection on bacteriophage MS2 virus-like particles. , 2011, Journal of molecular biology.

[29]  C. Davis,et al.  α and β Chains of Hemoglobin Inhibit Production of Staphylococcus aureus Exotoxins , 2007 .

[30]  A. Rajpal,et al.  Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus α-hemolysin. , 2013, Journal of molecular biology.

[31]  R. Novick,et al.  Quorum sensing in staphylococci. , 2008, Annual review of genetics.

[32]  Gordon Y C Cheung,et al.  The potential use of toxin antibodies as a strategy for controlling acute Staphylococcus aureus infections , 2012, Expert opinion on therapeutic targets.

[33]  P. Stern,et al.  Multiple mechanisms underlie HLA dysregulation in cervical cancer. , 2000, Tissue antigens.

[34]  K. Bayles,et al.  Identification of the Staphylococcus aureus vfrAB Operon, a Novel Virulence Factor Regulatory Locus , 2014, Infection and Immunity.

[35]  Denis Gris,et al.  Staphylococcus aureus α-Hemolysin Activates the NLRP3-Inflammasome in Human and Mouse Monocytic Cells , 2009, PloS one.

[36]  Roberta B Carey,et al.  Methicillin-resistant S. aureus infections among patients in the emergency department. , 2006, The New England journal of medicine.

[37]  M. Aman,et al.  Novel Structurally Designed Vaccine for S. aureus α-Hemolysin: Protection against Bacteremia and Pneumonia , 2012, PloS one.

[38]  H. Gresham,et al.  Nox2 Modification of LDL Is Essential for Optimal Apolipoprotein B-mediated Control of agr Type III Staphylococcus aureus Quorum-sensing , 2013, PLoS pathogens.

[39]  Blaise R. Boles,et al.  Hemoglobin Promotes Staphylococcus aureus Nasal Colonization , 2011, PLoS pathogens.

[40]  A. Lusis,et al.  Inactivation of a bacterial virulence pheromone by phagocyte-derived oxidants: new role for the NADPH oxidase in host defense. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  G. Núñez,et al.  A Critical Role for Hemolysins and Bacterial Lipoproteins in Staphylococcus aureus-Induced Activation of the Nlrp3 Inflammasome1 , 2009, The Journal of Immunology.

[42]  D. Peabody,et al.  A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2 , 2011, PloS one.

[43]  J. Suzich,et al.  Assessment of an Anti-Alpha-Toxin Monoclonal Antibody for Prevention and Treatment of Staphylococcus aureus-Induced Pneumonia , 2013, Antimicrobial Agents and Chemotherapy.

[44]  J. Bubeck Wardenburg,et al.  Staphylococcus aureus α-Toxin: Nearly a Century of Intrigue , 2013, Toxins.

[45]  V. Fowler,et al.  Where does a Staphylococcus aureus vaccine stand? , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[46]  Bruce S. Edwards,et al.  Selective Chemical Inhibition of agr Quorum Sensing in Staphylococcus aureus Promotes Host Defense with Minimal Impact on Resistance , 2014, PLoS pathogens.